242 related articles for article (PubMed ID: 25205036)
1. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
[TBL] [Abstract][Full Text] [Related]
2. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
3. Targeting XRCC1 deficiency in breast cancer for personalized therapy.
Sultana R; Abdel-Fatah T; Abbotts R; Hawkes C; Albarakati N; Seedhouse C; Ball G; Chan S; Rakha EA; Ellis IO; Madhusudan S
Cancer Res; 2013 Mar; 73(5):1621-34. PubMed ID: 23253910
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the DNA Damage Response by DNA-PKcs Inhibitory Phosphorylation of ATM.
Zhou Y; Lee JH; Jiang W; Crowe JL; Zha S; Paull TT
Mol Cell; 2017 Jan; 65(1):91-104. PubMed ID: 27939942
[TBL] [Abstract][Full Text] [Related]
5. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro.
Toulany M; Dittmann K; Fehrenbacher B; Schaller M; Baumann M; Rodemann HP
DNA Repair (Amst); 2008 Oct; 7(10):1746-56. PubMed ID: 18678286
[TBL] [Abstract][Full Text] [Related]
6. Alternative end-joining originates stable chromosome aberrations induced by etoposide during targeted inhibition of DNA-PKcs in ATM-deficient tumor cells.
de Campos Nebel M; Palmitelli M; Pérez Maturo J; González-Cid M
Chromosome Res; 2022 Dec; 30(4):459-476. PubMed ID: 35604590
[TBL] [Abstract][Full Text] [Related]
7. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
Sultana R; Abdel-Fatah T; Perry C; Moseley P; Albarakti N; Mohan V; Seedhouse C; Chan S; Madhusudan S
PLoS One; 2013; 8(2):e57098. PubMed ID: 23451157
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.
Sultana R; McNeill DR; Abbotts R; Mohammed MZ; Zdzienicka MZ; Qutob H; Seedhouse C; Laughton CA; Fischer PM; Patel PM; Wilson DM; Madhusudan S
Int J Cancer; 2012 Nov; 131(10):2433-44. PubMed ID: 22377908
[TBL] [Abstract][Full Text] [Related]
9. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.
Abdel-Fatah T; Arora A; Agarwal D; Moseley P; Perry C; Thompson N; Green AR; Rakha E; Chan S; Ball G; Ellis IO; Madhusudan S
Breast Cancer Res Treat; 2014 Jul; 146(2):309-20. PubMed ID: 24972688
[TBL] [Abstract][Full Text] [Related]
10. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.
Riabinska A; Daheim M; Herter-Sprie GS; Winkler J; Fritz C; Hallek M; Thomas RK; Kreuzer KA; Frenzel LP; Monfared P; Martins-Boucas J; Chen S; Reinhardt HC
Sci Transl Med; 2013 Jun; 5(189):189ra78. PubMed ID: 23761041
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
[TBL] [Abstract][Full Text] [Related]
13. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin.
Li K; Yan H; Guo W; Tang M; Zhao X; Tong A; Peng Y; Li Q; Yuan Z
Exp Cell Res; 2018 May; 366(1):24-33. PubMed ID: 29522753
[TBL] [Abstract][Full Text] [Related]
14. Interaction between DNA Polymerase β and BRCA1.
Masaoka A; Gassman NR; Horton JK; Kedar PS; Witt KL; Hobbs CA; Kissling GE; Tano K; Asagoshi K; Wilson SH
PLoS One; 2013; 8(6):e66801. PubMed ID: 23826138
[TBL] [Abstract][Full Text] [Related]
15. Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.
Liu Y; Efimova EV; Ramamurthy A; Kron SJ
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31189537
[TBL] [Abstract][Full Text] [Related]
16. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
Ali R; Alblihy A; Toss MS; Algethami M; Al Sunni R; Green AR; Rakha EA; Madhusudan S
Ther Adv Med Oncol; 2020; 12():1758835920974201. PubMed ID: 33425022
[TBL] [Abstract][Full Text] [Related]
17. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.
Chua ML; Horn S; Somaiah N; Davies S; Gothard L; A'Hern R; Yarnold J; Rothkamm K
Radiat Environ Biophys; 2014 May; 53(2):355-64. PubMed ID: 24622963
[TBL] [Abstract][Full Text] [Related]
18. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
[TBL] [Abstract][Full Text] [Related]
20. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
